Shattuck Labs, Inc.(STTK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,857 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
STTK Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Shattuck Labs, Inc. (STTK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STTK at 15.0/100 on a 32-signal composite quality model, placing it at rank #2,857 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of STTK by reported 13-F value include T. Rowe Price Investment Management, ADAGE CAPITAL PARTNERS GP, L.L.C., Redmile Group, based on the most recent SEC filings. STTK trades on the Nasdaq exchange and files with the SEC under CIK 1680367. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STTK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Shattuck Labs, Inc. directly from SEC EDGAR. Shattuck Labs, Inc.'s 13F Pro composite quality score has ranged between 3 and 29 since 2021, currently 15.0 — an improving long-term trajectory across 24 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-15.2M
ROIC
Q2 2026
-30.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-82.5% YoYNet Income
+35.3% YoYOperating Income
+36.1% YoYEPS (Diluted)
+53.0% YoYTotal Assets
-0.0% YoYOp. Cash Flow
+34.1% YoYFree Cash Flow
+34.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.0M -82.5% | $5.7M +245.3% | $1.7M +154.1% | $652.0K -97.8% | $30.0M +202.2% | $9.9M |
| Net Income | $-48.8M +35.3% | $-75.4M +13.6% | $-87.3M +14.4% | $-101.9M -126.7% | $-45.0M -22.9% | $-36.6M |
| Operating Income | $-51.5M +36.1% | $-80.6M +12.4% | $-92.0M +11.0% | $-103.3M -128.3% | $-45.3M -22.6% | $-36.9M |
| EPS (Diluted) | $-0.70 +53.0% | $-1.49 +27.3% | $-2.05 +14.9% | $-2.41 -125.2% | $-1.07 +54.7% | $-2.36 |
| Total Assets | $91.0M -0.0% | $91.0M -42.9% | $159.6M -22.3% | $205.3M -31.2% | $298.6M -14.4% | $349.0M |
| Operating Cash Flow | $-39.9M +34.1% | $-60.5M +25.5% | $-81.2M +14.0% | $-94.5M -65.4% | $-57.1M -69.7% | $-33.7M |
| Free Cash Flow | $-40.0M +34.0% | $-60.6M +25.8% | $-81.6M +23.1% | $-106.1M -63.1% | $-65.0M -89.2% | $-34.4M |
Get alerted when STTK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Shattuck Labs, Inc. including:
Top Institutional Holders of STTK
T. Rowe Price Investment Management, Inc.
$93.2M13,432,540 shADAGE CAPITAL PARTNERS GP, L.L.C.
$56.4M8,122,179 shRedmile Group, LLC
$47.8M6,892,033 shORBIMED ADVISORS LLC
$43.8M6,306,127 shProsight Management, LP
$41.3M5,957,877 shBlackRock, Inc.
$27.3M3,935,810 shFrazier Life Sciences Management, L.P.
$26.0M3,750,000 shNEXTBio Capital Management LP
$25.9M3,727,348 shDeep Track Capital, LP
$25.7M3,706,734 shVANGUARD CAPITAL MANAGEMENT LLC
$22.3M3,207,865 sh
| Fund | Value | Shares |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | $93.2M | 13,432,540 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $56.4M | 8,122,179 |
| Redmile Group, LLC | $47.8M | 6,892,033 |
| ORBIMED ADVISORS LLC | $43.8M | 6,306,127 |
| Prosight Management, LP | $41.3M | 5,957,877 |
| BlackRock, Inc. | $27.3M | 3,935,810 |
| Frazier Life Sciences Management, L.P. | $26.0M | 3,750,000 |
| NEXTBio Capital Management LP | $25.9M | 3,727,348 |
| Deep Track Capital, LP | $25.7M | 3,706,734 |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.3M | 3,207,865 |
More Healthcare Companies
View all Healthcare →Put STTK on your watchlist
Track score changes the day Shattuck Labs, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is STTK a good stock to buy?
13F Pro's AI-powered analysis of Shattuck Labs, Inc. (STTK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STTK are available on the STTK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STTK is classified as a small company.
Which hedge funds own STTK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STTK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Shattuck Labs, Inc.'s investment landscape.